NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides

NeuroBo Pharmaceuticals · 2024-01
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 1
No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON

Slide inventory

25
every slide · same image gating as the playbook
01
Slide 1
Features a stylized anatomical illustration highlighting the liver.front_matter
03
other
Open slide detailBeat · Team
04
summarize
Open slide detailBeat · ProblemLoop · Golden Circle
05
plan_implementation
Open slide detailBeat · ProblemLoop · Golden Circle
06
The slide uses a Gantt-style layout to map clinical phases to specific time periods.plan_implementation
Open slide detailLoop · Golden Circle
07
The slide uses a medical illustration of the liver to highlight the target organ.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
08
The slide uses a standard comparison table format to contrast a competitor (Resmetirom) with the company's own asset (DA-1241).compare_peers
Open slide detailBeat · SolutionLoop · Pattern Hunter
09
The diagram shows a biological pathway from steatosis to steatohepatitis to fibrosis, highlighting the role of GPR119 activation in modulating cellular responsepresent_solution
Open slide detailBeat · SolutionLoop · Pattern Hunter
10
The slide shows two heatmaps (17 inflammation genes, 22 stellate cell activation genes) and a biological pathway diagram.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
11
Includes specific study references and definitions for abbreviations like GPR119, MASH, and GLP-1.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
12
The slide presents 10 distinct bar charts comparing Control, DA, DA+DPP4i, and DPP4i groups, with statistical significance markers.analyze_data
Open slide detailBeat · SolutionLoop · Golden Circle
13
Includes study design details for a multicenter, randomized, double-blind, placebo-controlled trial.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
14
The slide uses a diagram to map the drug's mechanism of action to specific biological effects in the liver, pancreas, and immune system.present_solution
Open slide detailBeat · SolutionLoop · Golden Circle
15
front_matter
Open slide detailBeat · Market SizeLoop · Golden Circle
16
The table highlights DA-1726's dual agonist mechanism (GLP-1R/GCGR) as a key differentiator against standard GLP-1 agonists.compare_peers
Open slide detailBeat · Market SizeLoop · Golden Circle
17
The slide uses a hub-and-spoke diagram to illustrate the systemic effects of the hormone.present_solution
Open slide detailBeat · Market SizeLoop · Golden Circle
18
The slide uses preclinical data to demonstrate efficacy superiority over a market-leading GLP-1 agonist.compare_peers
Open slide detailBeat · Market SizeLoop · Golden Circle
19
The slide uses three distinct chart types to demonstrate efficacy and metabolic impact.compare_peers
Open slide detailBeat · Market SizeLoop · Golden Circle
20
Includes definitions for MAD, SAD, PK, PD, FPFV, and LPLV.present_framework
Open slide detailBeat · Market SizeLoop · Golden Circle
21
transition
Open slide detailLoop · Golden Circle
22
Includes footnotes regarding anti-dilution provisions and reverse stock split/warrant conversion context.analyze_data
Open slide detailLoop · Golden Circle
23
transition
Open slide detailLoop · Golden Circle
24
summarize
Open slide detailLoop · Golden Circle
25
state_next_steps